<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082836</url>
  </required_header>
  <id_info>
    <org_study_id>04-009</org_study_id>
    <secondary_id>MSKCC-04009</secondary_id>
    <nct_id>NCT00082836</nct_id>
  </id_info>
  <brief_title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma</brief_title>
  <official_title>A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan,&#xD;
      can locate cancer cells and either kill them or deliver radioactive cancer-killing substances&#xD;
      to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan&#xD;
      together with rituximab works in treating patients with recurrent primary CNS lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the absorbed radiation doses of CNS lesions after administration of indium In&#xD;
           111 ibritumomab tiuxetan (for imaging) in patients with recurrent primary CNS lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of a therapeutic dose of yttrium Y 90 ibritumomab tiuxetan in these&#xD;
           patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Determine the radiographic response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients receive rituximab IV on day 1. Within 4 hours after rituximab&#xD;
      administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes.&#xD;
      Patients then undergo whole body imaging. Patients whose dosimetry indicates that their CNS&#xD;
      lesion would receive a sufficient radioimmunotherapy dose receive a therapeutic dose of&#xD;
      yttrium Y 90 ibritumomab tiuxetan IV over 20-30 minutes on day 7.&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6&#xD;
      months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Dosimetry at 1, 24, and 48 hours</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by NCI common toxicty criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response at 1 and 3 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Recurrent disease&#xD;
&#xD;
                    -  Isolated CNS relapse of systemic NHL allowed&#xD;
&#xD;
               -  Primary CNS lymphoma&#xD;
&#xD;
          -  Measurable gadolinium-enhancing lesion on MRI of the brain&#xD;
&#xD;
          -  No impaired bone marrow reserve&#xD;
&#xD;
          -  No hypocellular bone marrow&#xD;
&#xD;
          -  No marked reduction in bone marrow precursors of one or more cell lines (granulocytic,&#xD;
             megakaryocytic, erythroid)&#xD;
&#xD;
          -  No pleural effusion&#xD;
&#xD;
          -  No chronic lymphocytic leukemia&#xD;
&#xD;
          -  No AIDS-related lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Adult&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious nonmalignant disease that would preclude study participation&#xD;
&#xD;
          -  No infection&#xD;
&#xD;
          -  No anti-murine antibody reactivity*&#xD;
&#xD;
          -  No human anti-mouse antibodies&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test NOTE: *Results must be available prior to study entry for&#xD;
             patients who received prior murine antibodies or proteins, other than rituximab&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Radiotherapy&#xD;
&#xD;
          -  No prior stem cell transplantation&#xD;
&#xD;
          -  No prior myeloablative therapies with autologous bone marrow transplantation or&#xD;
             peripheral blood stem cell rescue&#xD;
&#xD;
          -  No prior failed stem cell collection&#xD;
&#xD;
          -  More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
          -  No prior whole-brain radiotherapy&#xD;
&#xD;
          -  No prior external beam radiotherapy (involved field or regional) to &gt; 25% of active&#xD;
             bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery except diagnostic surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren E. Abrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

